Tyrogenex was founded on the science of maximizing the potency and minimizing the toxicity of tyrosine kinase inhibitors.

Tyrogenex is developing X-82, a dual VEGFR/PDGFR/CSF-1R inhibitor. We are investigating an orally administered treatment for patients with wet AMD and in patients with solid tumors. X-82 has been designed with the goal of having a favorable toxicity profile and better tolerability.

The commonality of wet AMD and cancer stems from uncontrolled angiogenesis or the growth of blood vessels from existing blood vessel tissue. Specifically, PDGF, or platelet-derived growth factor, is one of the proteins that regulates cell growth and division. In particular, it plays a significant role in blood vessel formation or angiogenesis. Uncontrolled angiogenesis is a characteristic of both cancer and wet AMD.

X-82 is currently in Phase 2 clinical trials for wet AMD and solid tumors.